February 24, 2023

Updated Results From the ADAURA Trial: Continued Disease-Free Survival Benefit With Adjuvant Osimertinib vs Placebo in EGFR-Mutated Stage IB–IIIA NSCLC

As reported in the Journal of Clinical Oncology by Roy S. Herbst, MD, PhD, of Yale Cancer Center and Yale School of Medicine, and colleagues, updated findings in the phase III ADAURA trial showed cont...

The ASCO Post

January 23, 2025

Getting a Lung Cancer Diagnosis Was Shocking

Dr. Ho, a non-smoking Asian American physician, shares her journey of being diagnosed with lung cancer, her successful treatment, and her advocacy work to raise awareness about the risk of lung cancer in never smokers.

The ASCO Post

January 31, 2024

Accelerated Hypofractionated Chemoradiation With Adaptive SABR Boost in Locally Advanced, Unresectable NSCLC

According to a U.S. single-center radiation dose-expansion study, chemoradiation with adaptively increased stereotactic ablative radiotherapy (SABR) boost doses was safe and effective in patients with...

The ASCO Post

August 08, 2024

EGFR- and ALK-Altered NSCLC: TKIs With Stereotactic Radiosurgery for Brain Metastases

The addition of upfront stereotactic radiosurgery to CNS-penetrant TKI treatment prolonged time to CNS progression vs TKI treatment alone in TKI-naive patients with brain metastases from EGFR- and ALK...

The ASCO Post

November 27, 2023

Iruplinalkib Demonstrates Improved Efficacy and Tolerance vs Crizotinib in ALK Inhibitor–Naive, Advanced ALK-Positive NSCLC

The novel ALK tyrosine kinase inhibitor iruplinalkib has demonstrated potential for a difficult-to-treat subset of patients with non–small cell lung cancer (NSCLC), according to data presented at the...

The ASCO Post

October 12, 2023

Nonmelanoma Skin Cancers May Have Higher Mortality Rate Than Melanoma

How do the mortality rates associated with nonmelanoma skin cancers and melanoma compare? A study presented at the recent European Academy of Dermatology and Venerology Congress 2023 investigated.

The ASCO Post

October 09, 2024

Stereotactic vs Hypofractionated Radiotherapy for Inoperable Stage I NSCLC

The Canadian phase III LUSTRE trial, reported in JAMA Oncology by Swaminath et al, evaluated local tumor control for stereotactic body radiotherapy vs hypofractionated conventional radiotherapy in pat...

The ASCO Post

August 10, 2023

First-Line Atezolizumab vs Single-Agent Chemotherapy in Patients With Advanced NSCLC Ineligible for Platinum-Based Chemotherapy

In the phase III IPSOS trial reported in The Lancet, Lee et al found that first-line atezolizumab improved overall survival vs single-agent chemotherapy in patients with advanced non–small cell lung c...

The ASCO Post

January 11, 2023

FoundationOne Liquid CDx Receives FDA Approval as a Companion Diagnostic for Entrectinib

On January 4, the U.S. Food and Drug Administration (FDA) approved FoundationOne Liquid CDx to be used as a companion diagnostic to identify patients with ROS1-positive non–small cell lung cancer or N...

The ASCO Post